News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRDL, under $2
NASDAQ: $CRDL SHORT SQUEEZE ALERTS
Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
NASDAQ: $CRDL
Cardiol Therapeutics MAvERIC-Pilot Study Results:
Safety: High tolerability and 95% compliance.
Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
NASDAQ: $CRDL
Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.
Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
NASDAQ: $CRDL
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler
MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for!
❤️Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study!
❤️Episodes of pericarditis per year substantially reduced
❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials
Congratulations to all long term shareholders!
NASDAQ: $CRDL BIG NEWS:
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.
Valued at $9 per share, assuming $609M in sales
Valued at $1 per share, assuming $132M in sales
NASDAQ: $CRDL RED TO GREEN, Looks Good
Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED
Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.
Valued at $9 per share, assuming $609M in sales by 2033
Valued at $1 per share, assuming $132M in sales by 2033
NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
NASDAQ: $CRDL lets See Red To Green,
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.
The company recently raised $13.5 million
NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts
The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
NASDAQ: $CRDL SHORT SQUEEZE ALERTS
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.
MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
Key Points:
Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales
Promising early results, potential approval by 2027, targeting $609M peak sales
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
$CRDL BIG SHORT SQUEEZE
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.
Cardiol had around $21 million in cash at the end of Q1
NASDAQ: $CRDL
Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.
The 12-month price target is $10
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
AI
